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Abstract
The frequency characteristics of the gene polymorphisms (FVL G1691A, FII G20210A, MTHFR C677T, MTHFR A1298C, 
MTRR A66G) associated with thrombophilia, hyperhomocysteinemia risk and different perinatal or pregnancy complications were 
studied. This examination was conducted among 130 planned-pregnancy healthy young women aged between 19 and 29 years. A 
gene mutation analysis was performed using a real-time polymerase chain reaction (real-time PCR). Factor V Leiden (FVL G1691A) 
and prothrombin gene (FII G20210A) mutations were not identified in the women surveyed. The frequency of the occurrence of the 
heterozygous FVL 1691G/A genotype associated with the risk of thrombosis during pregnancy was very low in these women (0.8%). 
The frequency of the MTHFR (methylenetetrahydrofolate reductase) 1298C/С mutant genotype was 11.5%, MTHFR 677T/Т – 5.4%, 
and MTRR (methionine synthase reductase) 66G/G – 31.5%. A combination of the MTHFR 677TT/1298CC and MTHFR 677TТ/
MTRR 66GG mutant genotypes, which significantly increased the risk of pregnancy loss and neural tube defects, were found to occur 
in 0.8% of the cases.
We concluded that selective thrombophilia screening (FVL G1691A and FII G20210A) based on prior personal and/or family 
history of venous thromboembolism was more cost-effective than a universal preconception screening in all planning pregnancy 
women. However, in order to decrease the risk of congenital anomalies and pregnancy complications associated with folate dependent 
homocysteine metabolism, preconception care should include folate supplementation. 
Keywords: gene polymorphism; factor V Leiden; prothrombin gene mutation; methylenetetrahydrofolate reductase; methionine 
synthase reductase; preconception care.
Introduction
The FVL G1691A and FII  G20210A gene mutations are the 
common types of inherited thrombophilias. A systematic review 
and meta-analysis of the prospective cohort studies suggest 
a link between the maternal FVL G1691A/FII G20210A and 
placenta-mediated pregnancy complications including pregnancy 
loss, small for gestational age newborns, pre-eclampsia and 
placental abruption [1]. Folic acid is essential for normal 
embryogenesis and the course of pregnancy. The MTHFR gene 
C677T polymorphism and the MTRR gene A66G polymorphism 
are associated with various types of pregnancy complications: 
neuraltube defects, congenital heart defects, early and late 
miscarriages,  uteroplacental  insufficiency,  Down  syndrome, 
placental abruption and others [4-12].
The aim of the study was to investigate the incidence of 
the FVL G1691A, FII G20210A, MTHFR C677T/A1298C and 
MTRR A66G gene polymorphisms in planned-pregnancy healthy 
young women.
Material and Methods
The study was approved by the Сhita State Medical Academy 
Ethics Committee. A cross-sectional descriptive study was 
conducted among 130 healthy planned-pregnancy young women 
aged between 19 and 29 years that did not have a pregnancy, 
family or individual history of venous thromboembolism. The 
FVL G1691A, FII G20210A, MTHFR C677T, MTHFR A1298C 
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and MTRR A66G gene mutation analysis was conducted by real-
time PCR from the samples randomly selected from the healthy 
individuals. Allele and genotype frequencies were calculated 
by direct counting. Hardy-Weinberg equilibrium was evaluated 
using a chi-square test.
Results
The FVL G1691A and FII G20210A gene mutations were 
not  identified  in  the  women  surveyed.  The  frequency  of  the 
normal homozygous FVL 1691G/G genotype was significantly 
higher than the heterozygous FVL 1691G/A genotype ((99.2% 
(129/130) and 0.8% (1/130), respectively; P<0.0001)). The 
1691A and 1691G allele frequencies for the FVL G1691A 
mutation were 0.996 and 0.004, respectively. Among these 
women, 98.5% (128/130) were homozygous (20210G/G) carriers 
of the FII G20210A, while 1.5% (2/130, P<0.0001) of them were 
heterozygous (20210G/A) carriers of the G20210A. The 20210A 
and 20210G allele frequencies for the FII G20210A mutation 
were 0.992 and 0.008, respectively (Table 1). 
In total, 115 (88.5%) of the women possessed the normal 
MTHFR  A1298C genotype.  The frequencies of the normal 
homozygotes (1298A/A) and the heterozygotes (1298A/C) 
were 46.2% (60/130) and 42.3% (55/130), respectively. The 
mutant alleles with the MTHFR 1298C/C genotype were found 
significantly less frequently when compared with the MTHFR 
1298A/A and the MTHFR 1298A/C genotypes – in 15 samples 
(11.5%, P<0.001).  The 1298A and 1298C allele frequencies 
for the MTHFR A1298C mutation were 0,673 and 0.327, 
respectively. 
 In this study, 123 of the 130 healthy young women had 
the normal MTHFR  C677T genotypes. The MTHFR 677С/С 
genotype was detected in 70 (53.8%) of these women. The 
MTHFR 677С/T genotype was observed in 53 (40.8%) cases. 
The 677T/T homozygotes for the MTHFR C677T mutation were 
found in 7 (5.4%) cases. The 677C and 677T allele frequencies for 
the MTHFR C677T mutation were 0.742 and 0.258, respectively. 
The frequency of the normal homozygous MTRR 66A/A 
genotype was significantly less than heterozygous MTRR 66A/G 
genotype ((27.7% (36/130) and 40.8% (53/130), respectively; 
P<0.05)). The 66G/G homozygotes for the MTRR A66G 
mutation were identified in the 41(31.5%) women surveyed. The 
677A and 677G allele frequencies for the MTRR A66G mutation 
were 0.481 and 0.519, respectively. 
The combined MTHFR 677TT/1298CC and MTHFR 
677TТ/MTRR  66GG  mutant  genotypes,  which  significantly 
increased the risk of pregnancy loss and neural-tube defects 
[9,13], were identified in 2 women: MTHFR 677TT/A1298CC – 
in 1 woman (1/130; 0.8%),  MTHFR 677TТ/MTRR 66GG – in 1 
woman (1/130; 0.8%).
Discussion
The presence of the mutations that promote thrombophilia 
in the genes responsible for the folate metabolism and for plasma 
coagulation is often associated with pregnancy failures and may 
be the underlying cause in some cases.   Incidentally, the FVL 
G1691A and FII G20210A gene mutations are associated mainly 
with recurrent spontaneous abortions, small for gestational age 
newborns, pre-eclampsia, and placental abruption [1,4,15]. The 
heterozygous genotypes for the FVL G1691A and FII G20210A 
mutations are associated with the risk of thrombosis in pregnancy 
of well under 1% (0.2% and 0.5%, respectively) [16].  In our 
study, the frequency of the heterozygous FVL 1691G/A genotype 
associated with a risk of thrombosis in pregnancy was very low 
(0.8%) among planned-pregnancy healthy young women.  
Many studies in the literature have discussed the subject 
of the role of the MTHFR and MTRR gene mutations as a risk 
factor for neural tube defects, congenital heart defects, recurrent 
spontaneous early abortions and late miscarriages, uteroplacental 
insufficiency, Down syndrome, placental abruption and others 
[4-12]. As shown in Table 2, the frequency of the MTRR 66G/G 
genotype in the women surveyed was higher than the normal 
MTRR 66A/A genotype (31.5% and 27.7%, respectively). The 
frequencies of the MTHFR 677T/T and MTHFR 1298C/C 
genotypes,  which  contain    mutant  alleles,  were  significantly 
less than frequencies of the normal  homozygous MTHFR 
677C/C and MTHFR 1298A/A genotypes (53.8% vs 5.4% 
and 46.2% vs 11.5%, respectively). The findings of the earlier 
studies have shown that the combined presence of the MTHFR 
677TT/1298CC and MTHFR 677TТ/MTRR 66GG genotypes 
highly increased the risk of pregnancy loss and neural tube 
defects [9,13]. The combined presence of the MTHFR C677T/
A1298C polymorphisms with mutant alleles was detected in 1 
woman (0.8%). The prevalence of the combined MTHFR 677TТ/
MTRR 66GG genotype was 0.8%, too. 
Conclusion
The results of our study showed the absence of the FVL 
G1691A and FII G20210A mutations in healthy planned-
pregnancy young women between 19 and 29 years of age. 
The frequency of the heterozygous FVL 1691G/A genotype 
associated with the risk of thrombosis in pregnancy was very 
Table 1. 
Frequencies of the FVL G1691A and FII G20210A gene polymorphisms 
in planned-pregnancy healthy young women (n=130).
Gene 
polymorphism
Genotype Allele 
frequency (Р)
FVL G1691A
GG  GA AA G A
129 (99.2%) 1 (0.8%)  0 0.996 0.004
FII G20210A
GG  GA AA G A
128 (98.5%) 2 (1.5%) 0 0.992 0.008
Table 2.
Frequencies  of  the  MTHFR  A1298C/С677Т  and  MTRR  A66G  gene 
polymorphisms in planned-pregnancy healthy young women (n=130).
Gene 
polymorphism
Genotype Allele 
frequency (Р)
MTHFR A1298C
АА АС СС А С
60 (46.2%) 55 (42.3%) 15 (11.5%) 0.673  0.327 
MTHFR С677Т 
СС СТ TТ С Т
70 (53.8%) 53 (40.8%) 7 (5.4%) 0.742 0.258
MTRR A66G 
AA AG GG A G
36 (27.7%) 53 (40.8%) 41 (31.5%) 0.481 0.519179                          T. E. Belokrinitskaya et al. / International Journal of BioMedicine 3(3) (2013) 177-179
low in these women. We concluded that selective thrombophilia 
screening (FVL G1691A and FII G20210A) based on prior 
personal and/or family history of venous thromboembolism was 
more cost-effective than a universal preconception screening 
in all planning pregnancy women. The high frequency of the 
MTRR and MTHFR gene polymorphisms was observed in the 
healthy planned-pregnancy young women (MTRR 66G/G - 
31.5%, MTHFR 1298C/C - 11.5%, and MTHFR 677T/T - 5.4%). 
However, in order to decrease the risk of congenital anomalies 
and pregnancy complications, preconception care should include 
folate supplementation. 
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